Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05154734 (ClinicalTrials.gov)	October 30, 2021	7/12/2021	Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders	Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders (BEAT NMO)	NMO Spectrum Disorder	Drug: Belimumab	Tianjin Medical University General Hospital	NULL	Recruiting	18 Years	N/A	All	12	Phase 1/Phase 2	China
2	NCT04767698 (ClinicalTrials.gov)	October 1, 2021	18/2/2021	Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis	Addition of Belimumab to B-cell Depletion to Produce Prolonged Remission of Relapsing-remitting Multiple Sclerosis Disease Activity	Multiple Sclerosis	Drug: Belimumab;Drug: Short-course Ocrelizumab;Drug: Continued Ocrelizumab	Johns Hopkins University	GlaxoSmithKline	Terminated	18 Years	N/A	All	3	Phase 2	United States